Details of the Drug

General Information of Drug (ID: DM4HQ52)

Drug Name
APL-2
Indication
Disease Entry ICD 11 Status REF
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 3 [1]
Cross-matching ID
TTD ID
D0P5LH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C3 (CO3) TTJGY7A CO3_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
2 National Cancer Institute Drug Dictionary (drug id 599816).
3 Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
4 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
7 Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.